Abstract

There are no pharmacological disease-modifying treatments that have an enduring effect to mitigate the seizures and comorbidities associated with established chronic temporal lobe epilepsy (TLE). Sodium selenate has been reported to have anti-epileptogenic effects if given before TLE onset. However, the majority of TLE patients already have established epilepsy when they present to the clinic. This study aimed to evaluate for disease modifying effects of sodium selenate treatment in the chronically epileptic rat post-status epilepticus (SE) model of drug-resistant TLE. Wistar rats underwent kainic acid-induced SE or sham. Ten-weeks post-SE, rats were randomly assigned to receive either sodium selenate, levetiracetam, or vehicle subcutaneous infusions continuously for 4 weeks. To evaluate the effects of the treatments, one week of continuous video-EEG was acquired before, during, and 4, 8 weeks post-treatment, followed by behavioral tests. Targeted and untargeted proteomics and metabolomics were performed on post-mortem brain tissue to identify potential pathways associated with modified disease outcomes. Telomere length has emerged as a potential biomarker of chronic brain conditions, was investigated as a novel surrogate marker of epilepsy disease severity in our current study. The results showed that sodium selenate treatment was associated with mitigation of measures of disease severity at 8 weeks post-treatment cessation; reducing the number of spontaneous seizures (p< 0.05), cognitive dysfunction (p< 0.05 in both novel object placement and recognition tasks), and sensorimotor deficits (p< 0.01). Moreover, in the brain post-mortem selenate treatment was associated with increased protein phosphatase 2A (PP2A) expression, reduced hyperphosphorylated tau, and reversed telomere length shortening (p< 0.05). Network medicine integration of multi-omics/ pre-clinical outcomes identified protein-metabolite modules positively correlated with the TLE phenotype. Our results provide evidence that treatment with sodium selenate results in a sustained disease-modifying effect in chronically epileptic rats in the post-KA SE model of TLE, including improved comorbid learning and memory deficits.

Data availability

All the metrodology and results form this work have been included in the manuscrit or as part of the supplementary material.Data has been deposited in Dryad https://doi.org/10.5061/dryad.37pvmcvnd

The following data sets were generated
    1. Casillas-Espinosa PM
    (2022) EEG and multi-omics data
    Dryad Digital Repository, doi:10.5061/dryad.37pvmcvnd.

Article and author information

Author details

  1. Pablo Miguel Casillas-Espinosa

    Department of Neuroscience, Monash University, Melbourne, Australia
    For correspondence
    pablo.casillas-espinosa@monash.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6199-9415
  2. Alison Anderson

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  3. Anna Harutyunyan

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  4. Crystal Li

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  5. Jiyoon Lee

    Department of Medicine, University of Melbourne, Parkville, Australia
    Competing interests
    The authors declare that no competing interests exist.
  6. Emma L Braine

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  7. Rhys D Brady

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  8. Mujun Sun

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  9. Cheng Huang

    Monash Proteomics and Metabolomics Facility, Monash University, Clayton, Australia
    Competing interests
    The authors declare that no competing interests exist.
  10. Christopher K Barlow

    Monash Proteomics and Metabolomics Facility, Monash University, Clayton, Australia
    Competing interests
    The authors declare that no competing interests exist.
  11. Anup D Shah

    Monash Proteomics and Metabolomics Facility, Monash University, Clayton, Australia
    Competing interests
    The authors declare that no competing interests exist.
  12. Ralf B Schittenhelm

    Monash Proteomics and Metabolomics Facility, Monash University, Clayton, Australia
    Competing interests
    The authors declare that no competing interests exist.
  13. Richelle Mychasiuk

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  14. Nigel C Jones

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  15. Sandy R Shultz

    Department of Medicine, University of Melbourne, Parkville, Australia
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2525-8775
  16. Terence J O’Brien

    Department of Medicine, University of Melbourne, Parkville, Australia
    For correspondence
    Terence.OBrien@monash.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7198-8621

Funding

National Health and Medical Research Council (APP1087172)

  • Pablo Miguel Casillas-Espinosa

University of Melbourne (603834)

  • Pablo Miguel Casillas-Espinosa

CIHR Skin Research Training Centre (PTJ - 153051)

  • Richelle Mychasiuk

National Health and Medical Research Council (Level 2 CDF)

  • Sandy R Shultz

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All procedures were approved by the Florey Animal Ethics Committee (ethics number 16-042-UM), adhered to the Australian code for the care and use of animals for scientific purposes and consistent with ARRIVE 2.0 guidelines

Copyright

© 2023, Casillas-Espinosa et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,291
    views
  • 286
    downloads
  • 23
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Pablo Miguel Casillas-Espinosa
  2. Alison Anderson
  3. Anna Harutyunyan
  4. Crystal Li
  5. Jiyoon Lee
  6. Emma L Braine
  7. Rhys D Brady
  8. Mujun Sun
  9. Cheng Huang
  10. Christopher K Barlow
  11. Anup D Shah
  12. Ralf B Schittenhelm
  13. Richelle Mychasiuk
  14. Nigel C Jones
  15. Sandy R Shultz
  16. Terence J O’Brien
(2023)
Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy
eLife 12:e78877.
https://doi.org/10.7554/eLife.78877

Share this article

https://doi.org/10.7554/eLife.78877

Further reading

    1. Immunology and Inflammation
    2. Medicine
    Haiyi Fei, Xiaowen Lu ... Lingling Jiang
    Research Article

    Preeclampsia (PE), a major cause of maternal and perinatal mortality with highly heterogeneous causes and symptoms, is usually complicated by gestational diabetes mellitus (GDM). However, a comprehensive understanding of the immune microenvironment in the placenta of PE and the differences between PE and GDM is still lacking. In this study, cytometry by time of flight indicated that the frequencies of memory-like Th17 cells (CD45RACCR7+IL-17A+CD4+), memory-like CD8+ T cells (CD38+CXCR3CCR7+HeliosCD127CD8+) and pro-inflam Macs (CD206CD163CD38midCD107alowCD86midHLA-DRmidCD14+) were increased, while the frequencies of anti-inflam Macs (CD206+CD163CD86midCD33+HLA-DR+CD14+) and granulocyte myeloid-derived suppressor cells (gMDSCs, CD11b+CD15hiHLA-DRlow) were decreased in the placenta of PE compared with that of normal pregnancy (NP), but not in that of GDM or GDM&PE. The pro-inflam Macs were positively correlated with memory-like Th17 cells and memory-like CD8+ T cells but negatively correlated with gMDSCs. Single-cell RNA sequencing revealed that transferring the F4/80+CD206 pro-inflam Macs with a Folr2+Ccl7+Ccl8+C1qa+C1qb+C1qc+ phenotype from the uterus of PE mice to normal pregnant mice induced the production of memory-like IL-17a+Rora+Il1r1+TNF+Cxcr6+S100a4+CD44+ Th17 cells via IGF1–IGF1R, which contributed to the development and recurrence of PE. Pro-inflam Macs also induced the production of memory-like CD8+ T cells but inhibited the production of Ly6g+S100a8+S100a9+Retnlg+Wfdc21+ gMDSCs at the maternal–fetal interface, leading to PE-like symptoms in mice. In conclusion, this study revealed the PE-specific immune cell network, which was regulated by pro-inflam Macs, providing new ideas about the pathogenesis of PE.

    1. Medicine
    Gabriel O Heckerman, Eileen Tzng ... Adrienne Mueller
    Research Article

    Background: Several fields have described low reproducibility of scientific research and poor accessibility in research reporting practices. Although previous reports have investigated accessible reporting practices that lead to reproducible research in other fields, to date, no study has explored the extent of accessible and reproducible research practices in cardiovascular science literature.

    Methods: To study accessibility and reproducibility in cardiovascular research reporting, we screened 639 randomly selected articles published in 2019 in three top cardiovascular science publications: Circulation, the European Heart Journal, and the Journal of the American College of Cardiology (JACC). Of those 639 articles, 393 were empirical research articles. We screened each paper for accessible and reproducible research practices using a set of accessibility criteria including protocol, materials, data, and analysis script availability, as well as accessibility of the publication itself. We also quantified the consistency of open research practices within and across cardiovascular study types and journal formats.

    Results: We identified that fewer than 2% of cardiovascular research publications provide sufficient resources (materials, methods, data, and analysis scripts) to fully reproduce their studies. Of the 639 articles screened, 393 were empirical research studies for which reproducibility could be assessed using our protocol, as opposed to commentaries or reviews. After calculating an accessibility score as a measure of the extent to which an article makes its resources available, we also showed that the level of accessibility varies across study types with a score of 0.08 for Case Studies or Case Series and 0.39 for Clinical Trials (p = 5.500E-5) and across journals (0.19 through 0.34, p = 1.230E-2). We further showed that there are significant differences in which study types share which resources.

    Conclusion: Although the degree to which reproducible reporting practices are present in publications varies significantly across journals and study types, current cardiovascular science reports frequently do not provide sufficient materials, protocols, data, or analysis information to reproduce a study. In the future, having higher standards of accessibility mandated by either journals or funding bodies will help increase the reproducibility of cardiovascular research.

    Funding: Authors Gabriel Heckerman, Arely Campos-Melendez, and Chisomaga Ekwueme were supported by an NIH R25 grant from the National Heart, Lung and Blood Institute (R25HL147666). Eileen Tzng was supported by an AHA Institutional Training Award fellowship (18UFEL33960207).